Seres Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Seres Therapeutics wird ein jährliches Gewinn- und Umsatzwachstum von 35.7% bzw. 17.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 44.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -417.8% betragen.

Wichtige Informationen

38.4%

Wachstumsrate der Gewinne

48.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.5%
Wachstumsrate der Einnahmen	56.5%
Zukünftige Eigenkapitalrendite	-313.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	12 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Sep 23

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth

Jul 13

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

May 08

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Mar 23

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Jan 30

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Dec 18

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Aug 31

Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 02

Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt

Dec 27

Seres Therapeutics Molecular Data On SER-109 Looks Good

Oct 04

Seres Therapeutics: Here We Go Again

Sep 09

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:MCRB - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	74	-67	N/A	-134	5
12/31/2025	11	-109	N/A	-97	7
12/31/2024	22	-102	N/A	42	7
6/30/2024	0	-162	-185	-182	N/A
3/31/2024	127	-83	-80	-76	N/A
12/31/2023	126	-114	-125	-117	N/A
9/30/2023	127	-141	-133	-123	N/A
6/30/2023	130	-153	-133	-123	N/A
3/31/2023	5	-265	-250	-239	N/A
12/31/2022	7	-250	-239	-229	N/A
9/30/2022	13	-231	-236	-228	N/A
6/30/2022	137	-103	-51	-40	N/A
3/31/2022	141	-87	-41	-30	N/A
12/31/2021	145	-66	-3	7	N/A
9/30/2021	155	-34	32	41	N/A
6/30/2021	30	-132	-117	-113	N/A
3/31/2021	31	-105	-101	-99	N/A
12/31/2020	33	-89	-94	-94	N/A
9/30/2020	23	-90	-90	-90	N/A
6/30/2020	29	-76	-83	-82	N/A
3/31/2020	35	-66	-69	-68	N/A
12/31/2019	35	-70	-78	-77	N/A
9/30/2019	38	-73	-50	-50	N/A
6/30/2019	40	-78	-56	-55	N/A
3/31/2019	32	-95	-70	-68	N/A
12/31/2018	28	-99	-65	-63	N/A
9/30/2018	21	-107	-99	-96	N/A
6/30/2018	35	-92	-79	-77	N/A
3/31/2018	33	-92	N/A	-77	N/A
12/31/2017	32	-89	N/A	-76	N/A
9/30/2017	32	-86	N/A	-76	N/A
6/30/2017	22	-97	N/A	-83	N/A
3/31/2017	22	-97	N/A	-83	N/A
12/31/2016	22	-92	N/A	44	N/A
9/30/2016	19	-86	N/A	53	N/A
6/30/2016	6	-82	N/A	53	N/A
3/31/2016	3	-67	N/A	69	N/A
12/31/2015	N/A	-55	N/A	-41	N/A
9/30/2015	N/A	-44	N/A	-33	N/A
6/30/2015	N/A	-34	N/A	-25	N/A
3/31/2015	N/A	-24	N/A	-17	N/A
12/31/2014	N/A	-18	N/A	-10	N/A
9/30/2014	N/A	-12	N/A	-8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MCRB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: MCRB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: MCRB wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: MCRBDie Einnahmen des Unternehmens (17.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: MCRBDie Einnahmen des Unternehmens (56.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: MCRB wird voraussichtlich in 3 Jahren unrentabel sein.

Seres Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to US$0.85 loss

Price target decreased by 14% to US$6.20

Consensus revenue estimates decrease by 63%, EPS upgraded

No longer forecast to breakeven

Price target increased by 7.7% to US$9.02

Price target increased by 15% to US$9.80

Recent updates

Lucien Selce and MKT Capital Issue Open Letter to Board of Seres Therapeutics Regarding Reported Engagement with Nestlé

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Seres Therapeutics, Inc. Announces Topline Clinical Data from Cohort 2 of its SER-155 Phase 1b Placebo-Controlled Study in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

First half 2024 earnings released: US$0.49 loss per share (vs US$0.20 loss in 1H 2023)

Consensus EPS estimates upgraded to US$0.85 loss

Seres Therapeutics, Inc. announced that it expects to receive $15.000001 million in funding from Société des Produits Nestlé S.A.

Seres Therapeutics, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth

Nestle's Health Unit to Take Full Control of Microbiota-Based Therapeutic

New minor risk - Market cap size

Price target decreased by 14% to US$6.20

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023)

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

Seres Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Seres Therapeutics Receives Non-Compliance Letter from The Nasdaq Stock Market LLC Related to Nasdaq Listing Rule 5450(a)(1)

New minor risk - Market cap size

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Consensus revenue estimates decrease by 63%, EPS upgraded

New minor risk - Financial position

Full year 2023 earnings: EPS exceeds analyst expectations

No longer forecast to breakeven

Seres Therapeutics Appoints Marella Thorell as Executive Vice President

Price target increased by 7.7% to US$9.02

Price target increased by 15% to US$9.80

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

Forecast to breakeven in 2026

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Consensus EPS estimates upgraded to US$0.98 loss, revenue downgraded

Price target decreased by 13% to US$8.54

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Seres Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Consensus EPS estimates fall by 34%

Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Second quarter 2023 earnings: EPS misses analyst expectations

Second quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 7.6% to US$10.17

Seres Therapeutics, Inc. and Nestle Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023

Seres Therapeutics, Inc. and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™

Consensus EPS estimates upgraded to US$0.96 loss

Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.61 loss in 1Q 2022)

Consensus estimates of losses per share improve by 13%

Price target decreased by 11% to US$11.00

Full year 2022 earnings: EPS and revenues miss analyst expectations

Seres Therapeutics' Investigational Ser-109 Ecospor Iv Study Data Publishes in Jama Network Open

Seres Therapeutics, Inc. Announces Initiation of Enrollment in SER-155 Phase 1B Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Insufficient new directors

Seres Therapeutics, Inc. Announces the Appointment of Claire M. Fraser, Ph.D., to Its Board of Directors

Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Consensus forecasts updated

Price target increased to US$14.33

Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

Seres Therapeutics, Inc. Announces the Publication of Phase 3 Clinical Data in the Journal of the American Medical Association

Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection

Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Seres Therapeutics: What The Market Is Missing

Consensus revenue estimates increase by 16%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M

Seres Therapeutics: The Good And The Challenging

Seres Therapeutics stock slips on $100M stock offering

Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?

Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens

Seres Therapeutics, Inc. Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection

Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting